CD30 and Lymphoma: Pathology in Practice

Slides:

Advertisements

Similar presentations

MYC/BCL2 protein coexpression contributes inferior outcome in DLBCL

Advertisements

Cell block: Monokeratin – rare dot Tissue biopsy: Monokeratin – positive On Slide Control.

Radioimmunotherapy Allison Spencer July 27, 2006.

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

How to Test New Antibodies for Immunohistochemistry Finding a good antibody Provide control slides Pre-treatments Detection methods Fixation methods.

Basics of Immunohistochemistry

C4d - staining: Comparison of methods C. Seemayer, A. Gaspert, M. Mihatsch.

MONOCLONAL ANTIBODIES

Host Defense Clinical and Experimental Immunologic Assays II Domenick Kennedy Dept. Microbiology and Immunology

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.

Expressing Surface Proteins to Target Cancer Cells Joe and Bobby.

Genes and Function: The Rewriting of our Textbooks of Pathology Presented By David Hafler at 2014 ASCO Annual Meeting.

Maude et al. BLOOD, 25 JUNE 2015 x VOLUME 125, NUMBER 26

SpecimenCTCTissue MarkerAntibodySourceAntibodySource ER monoclonal murine ER Janssen Diagnostics, LLC monoclonal murine, clone 1D5, 1:50, high pH.

Structure and function of blinatumomab. A

chimeric antigen receptor T-cell therapy for ALL

Immune Depletion, Immune Modulation, and Immunosuppression in MS: A Review.

Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

The Immune System. The Immune System Adaptive Immune Response.

T-Cell Exhaustion: Can We Overcome It in Cancer?

Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.

Discussion Outline Cells of the Immune System.

Peripheral T-Cell Lymphoma in 2013

Stepping Up Asthma Control for Effective Management

The Tumor Microenvironment

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Hybrid Model Integrating Immunohistochemistry and Expression Profiling for the Classification of Carcinomas of Unknown Primary Site Barbara A. Centeno,

Case Challenges in Chronic Migraine

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏ by Nicolas.

Figure 1 Chimeric antigen receptor (CAR) structures

The Nurse View: Best Practices in Multiple Myeloma

Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?

Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?

Optimizing Management of Advanced Bladder Cancer

Identification of the Tumor Cells in Peripheral T-Cell Lymphomas by Combined Polymerase Chain Reaction-Based T-Cell Receptor β Spectrotyping and Immunohistological.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

A Mitochondrial Power Play in Lymphoma

Recent Advances in the Treatment of Lymphoma

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Supplemental Material

CME-Certified 2012 Hematology Tumor Board Series: Practical Solutions to Current Clinical Challenges in B-Cell Lymphoma.

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

A B C D E CD20 CagA DAPI Merge Supplementary Figure 1.

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

A B C D E F Supplementary Fig. 1. Gating strategy for CD44+CD133+CD24+ B16 tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells.

A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.

Hiding in Plain Sight: How Cancer Evades the Immune System

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Fig. 2. GPC3 expression in normal and tumor tissues.

Interpretation of Anti-ALK Immunohistochemistry Results

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.

Tumor immunology.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

AMD Therapy: Where Are We Now and Where Are We Going?

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

Histological and immunohistochemical evaluation of primary central nervous system lymphoma. Histological and immunohistochemical evaluation of primary.

Antigen-specific CD8+ T cells express higher levels of PD-1 in animals that received the optimized SSX2 vaccine. Antigen-specific CD8+ T cells express.

Relationship of PMBL to Hodgkin lymphoma.

Distributions of CD4, Th1, and Th2 in adults (n = 16; A) and children (n = 50; B). Distributions of CD4, Th1, and Th2 in adults (n = 16; A) and children.

Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Supplementary Table 2. Antibodies and conditions used for the IHC studies.

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

Antiangiogenic effects of PI3K inhibitor NVP-BKM120.

BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment.

Comparison of PD-L1 mAbs in IHC across multiple tumor types.

Presentation transcript:

CD30 and Lymphoma: Pathology in Practice

Program Objectives

30 Years of CD30 in Lymphoma

Ber-H2 Monoclonal Antibody for CD30 Testing

CD30 Expression in Tumors

CD30 Expression in DLBCL

CD30 Expression in PTCL

CD30 Expression in PTCL (cont)

CD30 Testing in the Diagnostic Workup

CD30 Testing in the Diagnostic Workup: T-Cell Lymphomas

CD30 Testing in the Diagnostic Workup: B-Cell Lymphomas

Optimizing Fixation

Effects of the Length of Fixation

Optimizing Antigen Retrieval

Ber-H2 Antibody as the Standard

Practical Issues in CD30 Testing: Improving Antibody Performance

The Need for Standardization in CD30 Testing

CD30 IHC Validation Study

CD30 IHC Validation Study: Round 2

CD30 IHC Validation Study: Round 3

CD30 IHC Validation Study: Round 3 (cont)

Practical Issues in CD30 Testing: Strategies for Optimizing Results

Conclusions

Abbreviations

Abbreviations (cont)